Facebook
Twitter
LinkedIn
Forward2021 Pediatric Grand Rounds | Bench-to-Bedside Translation of Cellular Immunotherapy for Pediatric Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is a devastating pediatric diagnosis and refractory or multiple relapsed patients have dismal outcomes. Novel advancements in the field are occurring with CD33 CAR T-cells and FLT3 CAR T-cells, which are only available at select centers and does not currently include City of Hope.
The advancements in these CARs is a novel therapeutic strategy for this diagnosis and, while we cannot open these specific trials at City of Hope as we do not have the viral vector to make these CAR T-cells, we can refer patients to these centers in the interim and obtain insight from their experiences, should we have the ability to open our own AML CAR T-cell trials in the future.
Target Audience
City of Hope Pediatric Hematology/Oncology Physicians, Advance Practice Practitioners, City of Hope staff and research teams.
Learning Objectives
- Integrate management strategies into patient care (who and when to refer, how to care for afterwards).
- Apply principles of management to pediatric CAR T-cell immunotherapy.
- Discuss this therapeutic option with patients.
Additional Information
| Attachment | Size |
|---|---|
 AB 1195 Bibiliography - AML | 159.11 KB |
Virtual Meeting- Zoom
Sarah K. Tasian, MD Associate Professor of Pediatrics, Children's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, University of Pennsylvania Perelman School of Medicine and Abramson Cancer Center
Dr. Tasian has indicated that she receives Grant/Research Support from Beam Therapeutics, Gilead Sciences and Incyte Corporation, and is a Consultant for Aleta Biotherapeutics and Kura Oncology.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2021 Pediatric Grand Rounds | Bench-to-Bedside Translation of Cellular Immunotherapy for Pediatric Acute Myeloid Leukemia (AML) for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance